Centessa Pharmaceuticals(CNTA) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024 • Company advancing pipeline of potential best-in-class orexin receptor 2 (OX2R) agonists – Initiated Phase 1 clinical study with ORX750 being developed for sleep-wake disorders; Safety and ef icacy data in acutely sleep-deprived healthy volunteers assessed using Maintenance of Wakefulness Test (MWT) on track for 2H of 2024 – Nominated ORX142 as development candidate; Currently in IND enabl ...